New and sensitive HPLC-UV method for concomitant quantification of a combination of antifilariasis drugs in rat plasma and organs after simultaneous oral administration

2021 ◽  
Vol 13 (7) ◽  
pp. 933-945
Author(s):  
Andi Dian Permana ◽  
Elly Wahyudin ◽  
Ismail ◽  
Muh. Nur Amir ◽  
Muh. Raihan ◽  
...  
Keyword(s):  
Oral Administration ◽  
Lymphatic Filariasis ◽  
Wistar Rats ◽  
Rat Plasma ◽  
Simultaneous Analysis ◽  
Biodistribution Studies

A sensitive HPLC-UV method for simultaneous analysis of the drugs used in lymphatic filariasis treatment, namely IVM, ABZ and DOX has been validated. The method was applied in pharmacokinetic and biodistribution studies in Wistar rats.

scholarly journals The analysis of acetaminophen (paracetamol) and seven metabolites in rat, pig and human plasma by U(H)PLC–MS

Bioanalysis ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 485-500
Author(s):  
Rebecca Dargue ◽  
Isobelle Grant ◽  
Leanne C Nye ◽  
Andy Nicholls ◽  
Theo Dare ◽  
...  
Keyword(s):  
Stable Isotope ◽  
Sample Preparation ◽  
Oral Administration ◽  
Human Plasma ◽  
Wistar Rats ◽  
Rat Plasma ◽  
Mouse Serum ◽  
Internal Standards ◽  
Minimal Sample

A U(H)PLC–MS/MS method is described for the analysis of acetaminophen and its sulphate, glucuronide, glutathione, cysteinyl and N-acetylcysteinyl metabolites in plasma using stable isotope-labeled internal standards. P-Aminophenol glucuronide and 3-methoxyacetaminophen were monitored and semi-quantified using external standards. The assay takes 7.5 min/sample, requires only 5 μl of plasma and involves minimal sample preparation. The method was validated for rat plasma and cross validated for human and pig plasma and mouse serum. LOQ in plasma for these analytes were 0.44 μg/ml (APAP-C), 0.58 μg/ml (APAP-SG), 0.84 μg/ml (APAP-NAC), 2.75 μg/ml (APAP-S), 3.00 μg/ml (APAP-G) and 16 μg/ml (APAP). Application of the method is illustrated by the analysis of plasma following oral administration of APAP to male Han Wistar rats.

Simultaneous Determination of Imatinib and N-Desmethyl Imatinib in Rat Plasma and Tissues Using LC-MS/MS

2019 ◽  
Vol 15 (2) ◽  
pp. 121-129
Author(s):  
Zhi Rao ◽  
Bo-xia Li ◽  
Yong-Wen Jin ◽  
Wen-Kou ◽  
Yan-rong Ma ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Oral Administration ◽  
Parent Drug ◽  
Gradient Elution ◽  
Biological Tissues ◽  
Rat Plasma ◽  
Running Water ◽  
Liver And Kidney ◽  
The Brain

Background: Imatinib (IM) is a chemotherapy medication metabolized by CYP3A4 to Ndesmethyl imatinib (NDI), which shows similar pharmacologic activity to the parent drug. Although methods for determination of IM and/or NDI have been developed extensively, only few observations have been addressed to simultaneously determine IM and NDI in biological tissues such as liver, kidney, heart, brain and bone marrow. Methods: A validated LC-MS/MS method was developed for the quantitative determination of imatinib (IM) and N-desmethyl imatinib (NDI) from rat plasma, bone marrow, brain, heart, liver and kidney. The plasma samples were prepared by protein precipitation, and then the separation of the analytes was achieved using an Agilent Zorbax Eclipse Plus C18 column (4.6 × 100 mm, 3.5 µm) with gradient elution running water (A) and methanol (B). Mass spectrometric detection was achieved by a triplequadrupole mass spectrometer equipped with an electrospray source interface in positive ionization mode. Results: This method was used to investigate the pharmacokinetics and the tissue distributions in rats following oral administration of 25 mg/kg of IM. The pharmacokinetic profiles suggested that IM and NDI are disappeared faster in rats than human, and the tissue distribution results showed that IM and NDI had good tissue penetration and distribution, except for the brain. This is the first report about the large penetrations of IM and NDI in rat bone marrow. Conclusion: The method demonstrated good sensitivity, accuracy, precision and recovery in assays of IM and NDI in rats. The described assay was successfully applied for the evaluation of pharmacokinetics and distribution in the brain, heart, liver, kidney and bone marrow of IM and NDI after a single oral administration of IM to rats.

scholarly journals RESVERATROL INCLUSION COMPLEX WITH β-CYCLODEXTRIN (RCD): CHARACTERIZATION AND EVALUATION OF TOXICITY IN WISTAR RATS

2016 ◽  
Vol 9 (1) ◽  
pp. 27 ◽  
Author(s):  
V. S. K. Nishihira ◽  
N. J. Mezzomo ◽  
M. D. Baldissera ◽  
R. A. Vaucher ◽  
C. G. Pinto ◽  
...  
Keyword(s):  
Inclusion Complex ◽  
Oral Administration ◽  
Biochemical Parameters ◽  
Wistar Rats ◽  
Metabolic Diseases ◽  
Hematological Parameters ◽  
Density Lipoprotein ◽  
Blood Parameters ◽  
Control Group ◽  
Scanning Calorimetry

<p class="RSCB01ARTAbstract"><strong>Objective</strong>:<strong> </strong>The aim of this study was to characterise the resveratrol inclusion complex with β-cyclodextrin (RCD) and evaluate their toxicity in wistar rats.</p><p class="RSCB01ARTAbstract"><strong>Methods: </strong>The RCD were prepared in ultra-turrax. For characterization of the RCD were used: Fourier transform infra-red Spectroscopy, Nuclear Magnetic Resonance (NMR), Differential Scanning Calorimetry (DSC) and X-ray powder diffraction. The RCD and others 4 treatments were performed by the chronic oral administration in 35 rats during 60 ds. After the treatments they were euthanized and the serum blood were collected to analyzed some hemogram and biochemical parameters including aspartyl aminotransferase (AST); alanine aminotransferase (AST); phosphatase alkaline (ALP); total bilirubin (TB); direct bilirubin (DB); total protein (TP); total cholesterol (TC), triacylglycerol (TAG), very low-density lipoprotein (VLDL), high-density lipoprotein (HDL), calcium, iron and phosphate using fully automated biochemistry analyzer.</p><p class="RSCB01ARTAbstract"><strong>Results: </strong>The characterization results indicated a successful formation of the RCD. All hematological parameters analysed were within the normal values in all the groups. Furthermore, the hemogram and biochemical parameters were significantly (P&gt;0.05) similar to the control group.</p><p class="RSCB01ARTAbstract"><strong>Conclusion: </strong>The daily oral administration during 60 d of RCD are not harmful on blood parameters of Wistar rats. Thus, RCD can be used safely for treatment of some metabolic diseases.</p>

scholarly journals Pharmacokinetics Studies of 12 Alkaloids in Rat Plasma after Oral Administration of Zuojin and Fan-Zuojin Formulas

Molecules ◽  
2017 ◽  
Vol 22 (2) ◽  
pp. 214 ◽  
Author(s):  
Ping Qian ◽  
You-Bo Zhang ◽  
Yan-Fang Yang ◽  
Wei Xu ◽  
Xiu-Wei Yang
Keyword(s):  
Oral Administration ◽  
Rat Plasma
Sign in / Sign up

Export Citation Format

Share Document